Neoadjuvant chemotherapy in XXXX : A survival study.

@entity1 @entity3003 @entity43 @entity1349
CONTEXT: @entity1 with advanced @entity43 have a poor prognosis in spite of the best possible care. Primary debulking surgery has been the standard of care in advanced @entity43 ; however, it is associated with high mortality and morbidity rates as shown in various studies. Several studies have discussed the benefit of neoadjuvant chemotherapy in @entity1 with advanced @entity43 . AIMS: This study aims to evaluate the survival statistics of the @entity1 who have been managed with interval debulking surgery (IDS) from January 2007 to December 2009. MATERIALS AND METHODS: During the period from January 2007 to December 2009, a retrospective analysis of 104 @entity1 who underwent IDS for stage IIIC or IV @entity43 at our institute were selected for the study. IDS was attempted after three to five courses of chemotherapy with paclitaxal (175 mg/m(2) ) and @entity3003 (5-6 of area under curve). @entity1349 ( @entity1349 ) and progression free survival (PFS) were compared with results of primary debulking study from existing literature. @entity1349 and PFS rates were estimated by means of the Kaplan-Meier method. Results were statistically analyzed by IBM SPSS Statistics 19. RESULTS: The median @entity1349 was 26 months and the median PFS was 18 months. In multivariate analysis it was found that both @entity1349 and PFS was affected by the stage, and extent of debulking. CONCLUSIONS: Neoadjuvant chemotherapy, followed by surgical cytoreduction is a promising treatment strategy for the management of @entity43 .
